EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Nanotech Liquidia Hops IPO Wave as Lead Drug Faces Late-Stage Test

(Page 2 of 2)

treprostinal, including an inhaled version, Tyvaso. PAH drugs are United Therapeutics’ top revenue source, accounting for $670.9 million of the company’s $1.7 billion in 2017 sales. In a move to expand its PAH drug lineup, United Therapeutics in April reached a $141 million deal to acquire SteadyMed, a San Ramon, CA, company that is has developed a product that administers treprostinil via a skin patch for 48 straight hours. SteadyMed aims to make dosing of the drug more convenient for patients and also avoid the pain and skin reactions that can come from the injectable versions. The company expects to file for FDA approval of the product in the fourth quarter of this year.

Liquidia’s pipeline also includes a pain drug candidate. In addition to optimizing drug delivery, the company’s technology can also control the release of an active pharmaceutical ingredient. Its second drug candidate, LIQ865, is an injectable version of bupivacaine, a generic drug used to manage post-surgical pain. The company says its version of bupivacaine was developed to provide pain relief lasting up to five days, which is longer than currently available versions of the drug. Liquidia plans to start Phase 2 tests of LIQ865 in the second half of this year.

The PAH and pain drugs are not Liquidia’s first foray into drug development. PRINT is a platform technology and the company has used that platform to launch other ventures. In 2013, the company formed a subsidiary called Envisia Therapeutics, which used PRINT to develop eye drugs. Aerie Pharmaceuticals (NASDAQ: AERI) acquired most of Envisia’s assets in 2017. In 2014, Liquidia formed yet another company, Lq3, focused on oral health. That effort fizzled and Liquidia ended up shutting down Lq3 less than two years later.

Liquidia has raised $116.9 million from equity financing. It was one of the first biotech investments by the Bill & Melinda Gates Foundation, which pumped $10 million into the startup in 2011. The Gates Foundation owns a 7.5 percent stake in Liquidia, according to the IPO filing. The company’s largest shareholder is New Enterprise Associates, which owns an 18.7 percent stake. Other shareholders include Canaan Partners, Xeraya Capital, and Morningside Venture Investments.

The Liquidia IPO filing comes as revenue from collaborations dwindles. The Gates Foundation investment was followed by a partnership to research vaccines for the developing world. The final piece of the $1 million payment from that collaboration was recognized as revenue last December. The company says in the filing that it is not currently doing any work related to the pact and it does not expect to see additional revenue from the agreement.

For the last two years, most of Liquidia’s revenue has come from its GlaxoSmithKline (NYSE: GSK) partnership on inhaled drugs and vaccines. GSK declined to renew the vaccine part of the deal in 2016. Research on inhaled drugs continues, but has been scaled back and led to the cutting of an undisclosed number of Liquidia jobs, according to the filing. Liquidia reported $7.5 million in 2017 revenue, down 43 percent from the prior year. The company’s 2017 net loss was $29.1 million. As of March 31 of this year, Liquidia’s balance sheet showed $17.5 million in cash.

Anatomy of the lungs and heart image by Flickr user University of Liverpool Faculty of Health & Life Sciences via a Creative Commons license

Single PageCurrently on Page: 1 2 previous page